Ivemend - European Medicines Agency (EMA)
Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines. It is used in adults and children from 6 months of age who are undergoing …
IVEMEND is used in adults, adolescents, and children aged 6 months or older in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) …
Fosaprepitant - Wikipedia
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, [6] administered intravenously. It is a prodrug of aprepitant. …
福沙匹坦 - 维基百科，自由的百科全书
福沙匹坦 （Fosaprepitant）是一種 肿瘤 辅助 用药，用于肿瘤治疗过程中， 化疗 的辅助用药，防止化疗引起的恶心、呕吐。 化学特征為阿瑞匹坦的磷酸酯前药。 在 美国 的商品名 …
IVEMEND 150 mg - ADC.sk
Patrí do skupiny liečiv nazývaných antagonisty receptoru pre neurokinín 1 (NK 1). Používa u dospelých, dospievajúcich a detí vo veku 6 mesiacov a starších v kombinácii s inými liekmi na …
IVEMEND 150 mg powder for solution for infusion - medicines
2022年2月24日 · IVEMEND 150 mg powder for solution for infusion - Summary of Product Characteristics (SmPC) by Merck Sharp & Dohme (UK) Limited
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. IVEMEND 150 mg is …
Ivemend - Merck Sharp & Dohme B.V. - 药物在线
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is …
Ivemend - European Drugs Reference Encyclopedia
Ivemend is an anti‑emetic (a medicine that prevents nausea [feeling sick] and vomiting). It is used with other medicines to prevent nausea and vomiting caused by chemotherapy (medicines …
Fosaprepitant Dimeglumine | C37H56F7N6O16P | CID …
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is …